AstraZeneca Stock - Weekly review and sector comparison after muted trading

AstraZeneca stock is coming off a softer session on its primary listings while large pharma peers show mixed moves. This weekly review looks at how the drugmaker compares within the sector and where the stock currently stands.

Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 15:35 CET. Details in the imprint.

AstraZeneca (GB0009895292) is ending the week after a slightly weaker session on its main listings compared with broader equity benchmarks. Sector data show large pharma peers posted mixed performances over the same period, highlighting a selective market for defensives.

How the shares ended the week

On London Stock Exchange, AstraZeneca shares last traded around 13,286.00 pence, leaving the stock more than 15% below its 52-week high of 15,732.00 pence set in February 2026, according to the Financial Times market summary. FT data on AstraZeneca

In New York, the company’s American depositary shares recently closed at about $174.90 on Nasdaq, with a move of roughly -1.7% in the latest session versus a positive Standard & Poor's 500 index performance that day. Yahoo Finance session recap

Weekly performance and sector peers

Over the past five trading days, AstraZeneca has trailed some large pharma peers that benefited from selective buying in US health care and European defensives. Short-term underperformance follows a strong multi-year run driven by oncology and cardiovascular franchises.

Drugmakers such as Pfizer, Novartis and GlaxoSmithKline showed varied weekly moves as investors rotated within the sector based on pipeline news, valuation and dividend profiles. Against this backdrop, AstraZeneca’s softer week reflects stock-specific positioning more than a broad pharma sell-off.

How AstraZeneca makes its money

AstraZeneca generates most of its revenue from prescription medicines in oncology, cardiovascular, renal and metabolism, respiratory and immunology, and rare disease. Its oncology portfolio includes blockbusters such as Tagrisso and Imfinzi, while Farxiga anchors its cardiovascular and diabetes offering.

Where the stock trades today

AstraZeneca shares (GB0009895292) trade on London Stock Exchange at around 13,286.00 pence as of 06/19/2026, 15:20 CET.

Key facts on AstraZeneca stock

• Company: AstraZeneca plc
• ISIN: GB0009895292
• WKN: 886455
• Ticker: AZN
• Venue: London Stock Exchange (AZN:LSE)
• Price (as of 06/19/2026, 15:20 CET): 13,286.00 pence
• Market cap: around GBP 205 billion (as of 06/19/2026)
• Sector / Industry: Health Care / Pharmaceuticals & Biotechnology
• Index membership: FTSE 100
• Next earnings date: 07/25/2026 (company guidance)

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.